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LETTER TO THE EDITOR
 To the Editor:
In the May 2012 issue of Journal of 
Thoracic Oncology, we were encouraged 
to submit clinical response data regard-
ing epidermal growth factor receptor-
tyrosine kinase inhibitor (EGFR-TKIs) 
in patients with uncommon EGFR muta-
tions.1 In this letter we would like to share 
our experience of a case with an EGFR 
mutation that has not been described 
before.
In July 2011, a 59-year old white 
woman was referred to our hospital with 
a T2aN0M1b (stage IV) adenocarcinoma 
of the left lung. She had pleuritis cari-
nomatosa, lymphangitis carcinomatosa, 
multiple lung metastases in the contra-
lateral lung, and a distant metastasis 
in the seventh rib at the left side. She 
presented with an Eastern Cooperative 
Oncology Group performance score of 3. 
Her clinical situation was dominated by 
dyspnea and hypoxemia. She was a light 
smoker until 1988.
Molecular analysis was perfor-
med on a formalin-fixed and paraffin- 
embedded cell block of pleural fluid that 
was acquired by ultrasound-guided fine 
needle aspiration. After screening using 
real-time polymerase chain reaction fol-
lowed by high-resolution melting analy-
sis, exon 19 was further analyzed using 
direct sequencing and pyrosequencing 
(Pyromark, Qiagen, The Netherlands). A 
double mutation in exon 19 was found: 
c.2239_2240TT>CC: p.L747P.
Although the clinical relevance of 
this mutation is not known, we choose an 
initial treatment with gefitinib (at a daily 
dose of 250 mg). Response assessments 
with 6-weekly computed tomography 
scans revealed stable disease accord-
ing to Response Evaluation Criteria in 
Solid Tumors (RECIST) criteria during 6 
months of treatment. No significant gefi-
tinib toxicity was observed besides a mild 
grade 1 rash. The patient deceased after 6 
months and 1 week of gefitinib treatment 
without clear radiologic progression as a 
result of right heart failure caused by her 
lymphangitis carcinomatosa.
Patients with mutations in exon 19 
show favorable outcomes when treated 
with EGFR-TKI.2 We observed stable 
disease upon EGFR-TKI treatment in a 
patient with an adenocarcinoma of the 
lung that harbored a p.747P double-point 
mutation in exon 19.
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